Ocular Therapeutix Inc (NASDAQ:OCUL) currently has a daily average trading volume of 925.25K but it saw 854738 shares traded in last market. With a market cap of 1.17B USD, the company’s current market price of $7.45 came rising about 0.20 while comparing to the previous closing price of $7.44. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.77 and as low as $4.06. In the recent trading on the day, stock has struck highest price mark of $7.28 while lowest mark touched by it was $7.51.
Taking a look at 20-day trading activity of Ocular Therapeutix Inc (OCUL) gives us an average price of $7.82, while its current price level is -36.69% below from 52-week high level whereas it is 83.62% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $8.45 while that of 200 days or SMA-200 reads an average of $8.15. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.07% during that period while stretching the period over a month that decreases to 4.70%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.98 which implies that the stock is in neutral territory.
TD Cowen upgraded its recommendation for the stock as a “Buy” from “Hold” on June 20, 2024 while assigning a price target range of $7-$11. Piper Sandler issued its recommendations for the stock as it resumed the price target for the stock is $15.
Over the week, OCUL’s stock price is moving -8.30% down while it is -8.19% when we observe its performance for the past one month. Year-to-date it is -12.70% down and over the past year, the stock is showing an upside performance of 31.25%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -0.22 while estimate for next year EPS is -1.07. In next quarter, company is expected to be making quarterly sales of $16.79M as analysts are expecting the sales for current fiscal year at $63.77M and seeing the company making $72.46M in sales next year. Moreover, analysts are in estimates of $16.89M for current-quarter revenue.
Currently, Ocular Therapeutix Inc’s total number of outstanding shares is 156.65M with 1.06% of that held by the insiders while 91.08% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -40.98% and return on equity (ROE) at -96.89%. Stock’s beta reads 1.32. Stock has a price to book (P/B) ratio of 3.32 while price to sale or P/S ratio amounts to 19.08. Its return on asset (ROA) is -53.42% on average.
